Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients.

Justyna DurślewiczAnna Klimaszewska-WiśniewskaJakub JóźwickiPaulina AntosikKamil KozerawskiDariusz GrzankaMarcin Braun

Published in: Journal of cancer research and clinical oncology (2022)

In conclusion, the present study warrants further investigation into the biological and prognostic value of MATR3 as a potential prognostic marker in early-stage NSCLC patients.

Keyphrases

early stage
end stage renal disease
small cell lung cancer
ejection fraction
chronic kidney disease
single cell
prognostic factors
cell therapy
squamous cell carcinoma
patient reported outcomes
bone marrow
risk assessment
mesenchymal stem cells
patient reported
sentinel lymph node
epidermal growth factor receptor